Recursion Pharmaceuticals (RXRX) Change in Acquisitions & Divestments (2020 - 2023)

Recursion Pharmaceuticals (RXRX) has 4 years of Change in Acquisitions & Divestments data on file, last reported at $480000.0 in Q3 2023.

• Quarterly Change in Acquisitions & Divestments fell 99.22% year-over-year to $480000.0 in Q3 2023, while the trailing twelve-month figure through Dec 2024 was $480000.0 (changed 0.0% YoY) and the FY2023 annual result came in at $480000.0, down 99.79% from the prior year.
• Change in Acquisitions & Divestments eased to $480000.0 in Q3 2023, from $61.5 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $147.6 million in Q1 2022 to a low of -$595000.0 in Q4 2020.
• A 4-year average of $49.9 million and a median of $41.5 million in 2022 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2021 — Change in Acquisitions & Divestments surged 11728.74% — and 2023, when it slumped 99.22%.
• Tracing RXRX's Change in Acquisitions & Divestments over 4 years: stood at -$595000.0 in 2020, then surged by 11728.74% to $69.2 million in 2021, then decreased by 11.05% to $61.5 million in 2022, then tumbled by 99.22% to $480000.0 in 2023.
• The last three Change in Acquisitions & Divestments figures came in at $480000.0 (Q3 2023), $61.5 million (Q3 2022), and $21.4 million (Q2 2022), per Business Quant data.